1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI

Abstract

Standard therapies for patients (pts) with epidermal growth factor receptor–mutated (EGFRm) non-small cell lung cancer (NSCLC) that has progressed after treatment with third-generation (3rd-gen) EGFR tyrosine kinase inhibitors (TKIs) offer only a limited benefit. Human epidermal growth factor receptor 3 (HER3) is often expressed in primary NSCLC tumors, and HER3 expression is commonly observed in patients with EGFR mutations. HER3-DXd is a novel antibody-drug conjugate composed of a human anti-HER3 monoclonal antibody (patritumab) linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker.